 Subjects will participate in this study for approximately 14-17 weeks. This study has 2 periods: 1 a 1-2-week screening period with 2 visits where baseline cholesterol and other characteristics will be evaluated to determine study eligibility. This period also includes a 4-week washout for patients on prior lipid-lowering therapies; and 2 a 12-week treatment period with interim visits at weeks 4 and 8. 